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Several new methods have recently been developed for the treatment of malignant bone and soft tissue 
tumors, and many of these targeted therapies have yielded promising initial results in clinical settings. As 
more sarcomas become amenable to effective molecularly targeted therapy, the need to evaluate the 
synergistic effects of combination therapies with anticancer drugs will grow. Other immunologic 
therapies have also been reported, such as exogenous cytokines, dendritic cell (DC) therapy and peptide 
vaccines. Cryoimmunology has shown promising results in some malignant tumors after cryosurgery and 
is expected to influence the next generation of tumor immunotherapy. In this report, we describe the 
induction of a systemic antitumor immune response following liquid nitrogen cryotreatment of a 
destructive murine osteosarcoma. Combining tumor cryotreatment with DCs to promote tumor-specific 
immune responses enhanced systemic immune responses and inhibited metastatic tumor growth. We also 
describe the induction of a systemic antitumor immune response following reconstruction of malignant 





Promising developments building upon standard cancer therapies, such as chemotherapy, radiotherapy 
and surgery have dramatically improved patient survival for malignant bone and soft tissue tumors. For 
example, osteosarcoma is the most common primary malignant bone tumor. A standard protocol of 
neo-adjuvant chemotherapy, combined with wide local excision, improves five-year disease-free survival 
60% to 90% [1-7]. However, some patients are refractory to these treatments, and lung metastasis is often 
associated with a fatal outcome. Thus, a more effective systemic treatment is called for in these patients 
[8].  
1. Targeted therapies in bone and soft tissue sarcomas 
 Molecular targeting therapy is one of many novel therapies developed in the 1990’s that is effective 
against some carcinomas. However, these drugs have been embraced slowly for clinical use in malignant 
bone and soft tissue tumors in the clinic. Recently, there have been some reports of clinical trials utilizing 
molecular targeting therapy.  
   Sorafenib targets a tyrosine kinase inhibitor. Pacey et al. reported a Phase II trial of sorafenib (400 mg 
twice daily for 12 weeks or more) that included patients with advanced soft tissue sarcoma. One patient 
achieved a partial response and three patients achieved minor responses, out of 26 patients [9]. The other 
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Phase II study of sorafenib in patients with metastatic or recurrent sarcomas reported that five of 37 
patients with angiosarcoma had a partial response (response rate, 14%) [10]. As for antiangiogenic and 
immunomodulatory drugs, the most important regulator in angiogenesis is vascular endothelial growth 
factor (VEGF), which is targeted by several drugs. One such drug is the tyrosine kinase inhibitor 
semaxanib. Phase I data showed moderate drug-related toxicities. In 31 patients with soft tissue sarcoma, 
one minor response and five stable diseases (SD) were demonstrated [11, 12]. Another anti-VEGF agent 
being tested is bevacizumab. A Phase II trial in combination with doxorubicin at 75 mg/m2 in 17 patients 
with metastatic soft tissue sarcoma was recently reported. Two partial responses (PR) were observed, 11 
patients had SD for four or more cycles. The 12% response rate was no greater than that observed for 
single-agent doxorubicin therapy. However, the 65% SD in patients suggests further study is warranted 
for these tumors [13]. Chemotherapy combined with bevacizumab is effective for soft tissue sarcomas. 
Dramatic improvement was achieved with inoperable angiosarcoma with combination paclitaxel and 
bevacizumab chemotherapy [14]. Other combination therapies with sequential high-dose (HD) ifosfamide, 
carboplatin and etoposide refractory to standard chemotherapy in patients with sarcoma and germ cell 
cancer (GCC) have been reported. One almost complete response in a patient with GCC, previously 
progressive with three preceding protocols, was observed. Six patients had a partial response (sarcoma 
4/13 patients; GCC 2/3 patients), and five patients achieved stable disease (sarcoma 5/13 patients) [15]. 
Of these, the most extensively studied is the tyrosine kinase inhibitor pazopanib. In a Phase II study, 
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pazopanib produced a progression rate arrest at three months sufficient to justify cohort expansion in 
patients with synovial sarcoma, leiomyosarcoma and a group of other tumors including those of vascular 
origin, but was relatively inactive against adipocytic tumors [16]. 
Imatinib is a molecularly targeted drug that inhibits tyrosine kinase, as well as type III tyrosine kinase 
receptors, such as platelet-derived growth factor receptor (PDGFR), KIT, colony-stimulating factor 1 
receptor (CSF-1R), and discoidin domain receptor (DDR). KIT-positive gastrointestinal stromal tumors 
(GISTs), and PDGFR-positive dermatofibrosarcoma protuberans (DFSP) have been reported to be 
responsive to imatinib treatment. A Phase II trial of imatinib in patients with relapsed or refractory 
KIT-positive (excluding GISTs) or PDGFR-positive sarcomas was recently concluded. Twenty-two 
patients were evaluated for response. The response rate with a 600 mg/day dose of imatinib was 4.5% (0 
complete responses, 1 partial response), however, this result did not indicate effectiveness of imatinib 
monotherapy in patients with relapsed or refractory KIT-positive (excluding GISTs) or PDGFR-positive 
sarcomas [17]. Neither long-lasting freedom from disease progression nor clinical benefit was observed 
for advanced chondrosarcoma in a Phase II trial[18]. 
 
2. Immunological treatment in bone and soft tissue sarcomas 
Advances in basic tumor immunology and preliminary evidence for clinical activity of immunotherapy in 
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select settings have sustained optimism that immunotherapy will find an established place in cancer 
therapy. As for bone and soft tissue sarcoma, there are a number of clinical trials of immunotherapy 
currently, and we highlight some positive data from select studies in some detail below.   
Cytokine therapy (interleukin-2: IL-2)  
Luksch et al. have reported a clinical trial in osteosarcoma using IL-2, in which 18 children with 
localized osteosarcoma received four IL-2 courses (9x106 IU/ml/day x4), alternated with pre- and 
post-operative multiple chemotherapies. The results showed that intensive chemotherapies have no effect 
on IL-2-induced immune activation, and suggest a role for NK cells in the control of osteosarcoma [19]. 
Dendritic cell immunotherapy  
Dendritic cells (DCs) are effective professional antigen presenting cells with the ability to prime both 
primary and secondary immune responses to tumor antigens. One Phase I clinical study using DCs 
against solid tumors in children, including osteosarcoma, has been reported. In this series, one patient 
with metastatic fibrosarcoma demonstrated a strong positive response without obvious toxic side effects 
[20]. The other clinical trial of DC vaccination was for chondrosarcoma. Immunotherapy with allogeneic 
DCs stimulated with tumor cell lysates was demonstrated to be feasible, safe and well tolerated. 
Unfortunately, this study did not observe any clinical or immune response following vaccination. CD4+ 




Tumor-specific peptide immunotherapy 
Immunotherapy clinical trials are being conducted using a Wilms tumor (WT1) peptide for metastatic 
alveolar rhabdomyosarcoma. The patient received weekly intradermal injections of 
HLA-A*2404-restricted, 9-mer WT1 peptide against residual bone disease. After three months, her bone 
disease disappeared, concurrent with an increase in the frequency of WT1-specific cytotoxic T 
lymphocytes (CTLs) [22]. Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) antibodies have been 
employed in a clinical Phase II study coordinated by the Memorial Sloan-Kettering Cancer Centre in New 
York. The purpose of this clinical trial is to determine whether immune therapy with anti-CTLA-4 
antibody is effective in patients with advanced synovial sarcoma. A total of 17 patients will be recruited. 
In this study, the investigators are trying to induce an immune response against synovial sarcoma with 
anti-CTLA-4 antibody in recurrent disease [23, 24]. 
Combination with immunotherapies 
Mackall et al. reported a new immunotherapeutic regimen for recurrent or metastatic Ewing’s sarcoma 
family of tumors or alveolar rhabdomyosarcoma. Combinations of autologous T cells, influenza 
vaccinations, and DCs pulsed with peptides derived from tumor-specific translocation breakpoints and E7 
with or without recombinant human interleukin-2 showed minimal toxicity and favorable survival (43% 
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of five-year overall survival for immunotherapy patients compared with 15% for patients without 
immunotherapy) [25]. 
 
3. Cryosurgery in carcinomas 
The first documented uses of cryosurgery in the treatment of malignancy dates back to the 1840s using 
crushed ice and salt to treat superficial cancers [26]. However, it was not until the 1960s that this 
technology was advanced enough to be used in the treatment of primary and secondary malignancies [27]. 
Recently, cryosurgery using liquid nitrogen has been successfully used for the ablation of tumors in the 
liver [28], prostate [29] and kidney [30], and the palliative treatment of locally advanced breast cancers 
[31].  
Cryosurgery induces tumor cell death directly by causing damage to cell membranes and organelles and 
indirectly by causing vascular compromise through thrombosis of small vessels [32, 33]. With decreasing 
temperatures, the cells dehydrate and proteins are damaged because of high solute concentration, resulting 
in damage to the membranes and disruption of the enzymatic machinery of the cell. With faster cooling, 
ice crystals form inside the cells, damaging cell membranes and organelles by mechanical effects. With 
repeated freezing, thermal conductivity of tissue increases and spreads the damage. The indirect damage 
to cells occurs through vascular ischemia, resulting in cell death. Vessel wall damage can occur because 
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of perivascular cellular hydration, resulting in vessel distension and mechanical injury, or from direct cell 
damage to endothelial cells lining the vessels. Both pathways ultimately lead to increased permeability, 
edema, and a coagulation cascade, giving rise to microthrombi in vessels and tissue ischemia. 
Reperfusion injury is also proposed to play a role in the cell damage [34]. 
4. Cryosurgery in bone and soft tissue sarcomas 
 There have been some reports of cryosurgery for bone tumors.  Marcove et al. reported the first 
cryosurgery for primary and metastatic bone tumors in 1968 [35]. They used cryosurgery as a therapy for 
benign bone tumors of Aneurysmal bone cyst [36], giant cell tumor [37], chondroblastoma [38], 
malignant bone tumor of chondrosarcoma [39] and osteogenic sarcoma [40]. The treatment protocols 
were that, following tumor curettage, liquid nitrogen was poured into the bone cavity and then allowed to 
thaw. Freeze-thaw cycles were repeated 2 to 3 times to obtain maximum tissue necrosis. This method was 
difficult for treating tumor margins. Tsuchiya et al. developed a new cryosurgery method for 
reconstruction for malignant bone tumors using tumor-bearing autografts treated with liquid nitrogen. The 
operative technique consisted of en bloc excision of the tumor, removal of soft tissue, curettage of the 
tumor, drilling and preparation for internal fixation or prosthetic replacement before incubation for 20 
minutes in liquid nitrogen, thawing at room temperature for 15 minutes, thawing in distilled water for ten 
minutes, followed by internal fixation with an intramedullary nail, plate or composite use of prosthetic 
replacement [41] (Figure 1). A newly modified technique using pedicle frozen autografts to save the 
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continuity of anatomical structures was reported recently [42] (Figure 2).  
 
5. Cryoimmunology in carcinomas 
Previous reports have suggested that the immune system is activated by cryosurgery. The immunologic 
effects of cryosurgery [43] were first documented by Shulman et al. [44], who demonstrated the 
production of antibodies against rabbit male reproductive tissues after freezing. These antibodies, which 
reached a peak 7-10 days after cryoablation, were found to be tissue- and species-specific. Ablin et al. 
reported that spontaneous regression of metastases occurred after cryosurgery of a primary prostate tumor 
in clinical cases and coined the term “cryoimmunotherapy” [45, 46]. They found enhancement of immune 
responses after repeated in situ freezing, which they explained was due to multiple inoculations with the 
same antigen. These anecdotal reports of regression of metastases in patients, whose primary tumors were 
treated by cryosurgery, further stimulated interest in the immunostimulatory potential of cryoablation. 
 In animal models, cryosurgery of tumor tissue resulted in the rejection of tumor re-challenge and in 
inhibition of secondary and metastatic tumor growth. Neel et al. [47] showed increased resistance to 
tumor re-challenge in cryosurgically treated mice as compared to those mice whose tumors were 
amputated, ligated, or not treated. The mechanism of cryosurgery-induced immune responses was thought 
to be due to increased tumor-specific antibodies that arose after freezing. Bagley et al. [48] demonstrated 
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that lymphocytes from cryosurgically treated animals were cytotoxic against the tumor cells the animals 
had been inoculated with, thus showing cell-mediated immunity to be at least partially responsible for the 
antitumor effects observed following cryosurgery. Misao et al. [49] further characterized the kinetics of 
cryoablation-induced antitumor immunity using metastasizing rat mammary tumor No. 1 in 
Spague-Dawley rats. They observed an initial decrease in antitumor immunity after cryosurgery, which 
later increased gradually to reach a peak at 10 weeks after cryosurgery. The initial dip was considered as a 
result of the activation of suppressor cells due to of cryosurgical stress or slow and steady absorption of 
antigens. Joosten et al. [50] demonstrated that freezing of one of the tumors was superior to excision in 
retarding the growth of the untreated tumor. They also demonstrated decreased metastatic growth of the 
melanoma cell line MV3 in mice treated by cryoablation as compared with surgical resection. Within six 
hours of the procedure, mice whose tumors were frozen had higher interleukin-1 and tumor necrosis 
factor levels than mice whose tumors were excised. Sabel et al. [51] also examined the response triggered 
by cryosurgery in mammary adenocarcinoma (MT-901) in BALB/c mice. They found higher levels of the 
type 1 helper cytokines interleukin-2 and interferon gamma and higher tumor rejection rates in animals 
treated with cryoablation. Cryoablation also increased natural killer cell activity as compared with surgery 
alone. The many promising results lead to questions about the mechanism(s) of cryoimmunology. 
Cryoablation of tumor tissue leads to coagulative necrosis of cells. This causes a cellular breakdown and 
release of intracellular contents and proinflammatory cytokines. In addition to cytokines, the release of 
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heat shock proteins, DNA, RNA, or the chromosomal protein high mobility group box chromosomal 
protein 1 serves as a stimulus for the innate immune response and attracts granulocytes, macrophages, and 
natural killer (NK) cells. These cells further release cytokines and chemokines.  
DCs are critical professional antigen-presenting cells (APCs), crucially important in the capture, 
processing, and presentation of tumor antigens to tumor-specific T cells [52]. Necrotic tumor debris 
contains endogenous “danger signals,” such as high mobility group box chromosomal protein 1, required 
for the activation and maturation of APCs. DCs reach the damaged tissue, take up tumor antigens in the 
context of inflammation and abundant cytokines, and undergo a change in phenotype with the 
upregulation of cell surface markers, such as costimulatory, adhesion, and integrin molecules [53]. The 
activated APCs migrate to tumor-draining lymph nodes where they present tumor antigens on major 
histocompatibility complex molecules, as well as costimulatory signals, to tumor-specific T cells, 
inducing their activation. Activated, effector CD4 T cells can attack major histocompatibility complex 
Class II+ tumors and provide help to a variety of antitumor effector cells, including CD8+ cytotoxic T cells, 
B cells, and macrophages [34]. 
Adjuvant therapy has also been considered in order to enhance immunity after cryosurgery. Urano et al. 
described that cryosurgery combined with administration of the polysaccharide Krestin increased 
cytokine production and cytotoxic activity [54]. Lubaroff et al. reported that cryosurgery combined with 
bacillus Calmette-Guerin (BCG) was capable of producing antitumor immunity that rejected from 
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re-challenge [55]. Udagawa et al. recently reported that cryoablation combined with intra-tumoral 
administration of BCG-CWS and DCs induced tumor-specific T cells and reduced metastases [56]. 
Recently, there have been reports on the use of cryosurgery with injection of DCs as antigen presenting 
cells. Machilenkin et al. reported that intratumoral injections of DCs following cryosurgery led to local 
tumor-induced, tumor-specific cytotoxic T lymphocytes responses as well as reduced lung metastasis and 
a prolonged survival rate in mouse models of lung carcinoma and melanoma [57]. Den Brok et al. 
reported that the immatured DCs injection following cryoablation induced DC maturation and antitumour 
immunity in a mouse melanoma cell model [53]. Udagawa et al. reported that intratumoral administration 
of dendritic cells stimulated with Bacillus Calmette-Guerin cell wall components, which matures and 
activates DCs, following cryoablation induced tumor-specific CD8+ T cells and increased the antitumor 
effect in a mouse colon cancer model [58]. In a clinical study, Osada et al. reported that patients with 
unresectable liver tumors treated with cryosurgery displayed tumor necrosis not only in the treated areas, 
but also outside of the treated areas, and had increased serum IL-6, TNF-alpha, and Th1/Th2 ratio. 
However, patients with a localized effect who did not show reduced satellite lesions did not have 
increased cytokines and required another immune activation method [59]. 
 
5. Cryoimmunology in bone and soft tissue sarcomas 
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Similar to other malignant tumors, cryoimmunology for malignant bone and soft tissue tumors has 
received a great deal of interest. We reported the possible induction of a systemic antitumor immune 
response induced by re-implantation of destroyed tumor tissue treated with liquid nitrogen in a murine 
osteosarcoma model [60]. Tissue from the tumor was frozen in liquid nitrogen, thawed in distilled water 
and re-implanted in the same animal. In addition, some mice received the immunological response 
modifier OK-432. Re-implantation of tumor tissue after cryotreatment activated immune responses and 
inhibited metastatic tumor growth, and OK-432 synergistically enhanced the antitumor effect after 
treatment. Kawano et al. reported combining tumor cryotreatment with DC immunotherapy in order to 
promote tumor-specific immune responses. They investigated whether cryotreatment with DCs could 
enhance systemic immune responses and inhibit metastatic tumor growth in a same model. In order to 
evaluate the activation of antitumor immunity, they prepared six groups of C3H mice: excision only, DCs 
without reimplantation of the cryotreated primary tumor, reimplantation of the cryotreated primary tumor 
alone, DCs combined with reimplantation of the cryotreated primary tumor, DCs exposed to cryotreated 
tumor lysates without reimplantation of the cryotreated primary tumor, and DCs exposed to cryotreated 
tumor lysates with reimplantation of the cryotreated primary tumor. They then compared antitumor 
immunity between the groups. Mice that received DCs exposed to cryotreated tumor lysates with 
reimplantation of the cryotreated primary tumor group had high serum interferon-γ (IFN-γ), reduced 
pulmonary metastases, and increased numbers of CD8+ T lymphocytes in metastatic areas. Their 
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conclusion was that combining tumor cryotreatment with DCs enhanced systemic immune responses and 
inhibited metastatic tumor growth [61]. We also evaluated the possible induction of a systemic antitumor 
response in reconstructions of malignant bone tumors using frozen autografts treated with liquid nitrogen 
in clinical settings. We have treated 24 cases of malignant bone tumors by this treatment and studied the 
associated immune responses. Our study cohort consisted of 14 men and 10 women, with a mean age of 
38.3 years (range: 12 to 73). The tumors were located in 12 femurs, 6 tibias, 3 pelves, 2 humorous and 
one radius. The diagnoses of malignant bone tumor were 14 osteosarcoma, 8 metastatic bone tumors (3 
renal cell carcinoma, 1 breast cancer, osteosarcoma, hepatocellular carcinoma, colon cancer and ureter 
carcinoma) and 2 chondrosarcoma. Blood samples were collected from the patients before surgery and 
one and three months after surgery for the measurement of IFN-γ and IL-12 in order to assess immunity. 
At the final follow-up, five patients had died (mean follow-up, 13.8 months), 15 remained free from 
disease (mean follow-up, 19.9 months) and four patients were alive with disease. The mean INF-γ relative 
concentrations one and three months after surgery compared with before surgery were 155.1 and 268.3%, 
and mean IL-12 relative concentrations were 190.6 and 432.2%, respectively. Composite values for all 24 
patients showed progressive increases in INF-γ and IL-12 levels one and three months after surgery 
(Table 1). We attempted adjuvant therapy cryotreatment with DC immunotherapy in clinical trials in order 
to develop cryoimmunological therapy for malignant bone and soft tissue tumors. Although preliminary, 
we have some initial results for liquid nitrogen cryotreatment combined with DC immunotherapy in an 
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osteosarcoma patient. This is a 17-year-old girl with osteosarcoma of distal femur with multiple 
metastases in pelvis, lumbar, humerus and lung. After the standard treatment of neoadjuvant 
chemotherapy, we performed wide excision with liquid nitrogen cryotreatment and composite 
reconstruction of the right femur, followed by adjuvant chemotherapy. We performed DC immunotherapy 
twice. After DC immunotherapy, the lung metastasis was stable for 12 months and pelvic metastases were 
partially reduced. The final follow-up was DOD two years after the initial treatment, at which time we 
considered the combination of liquid nitrogen cryotreatment and DC immunotherapy to have limited 
tumor growth at least partially.  
Conclusions 
Cryoimmunology continues to evolve, and is impacted by further investigations into cryoimmunological 
mechanisms and novel techniques to detect disease. The need for research is evident in several aspects of 
cryoimmunology, especially in better understanding how the immune system becomes activated, 
translating these discoveries to the clinic and applying cryoimmunology to malignant bone and soft tissue 
tumors. The benefits provided by cryoimmunology combined with adjunct chemotherapy require 
investigation. Preclinical work with experimental tumors shows cryo-immunologic responses, but, as yet, 
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Figure 1: Schematic diagram of cryotreatment using liquid nitrogen (free frozen method) 
(a) Bone tumor in the ilium 
(b) Internal hemipelvectomy and tumor curettage  
(c) The specimen contained with tumor was frozen in liquid nitrogen 
(d) Reconstruction using a plate with bone cement 
 
Figure 2: Schematic diagram of cryotreatment using liquid nitrogen (pedicle frozen method) 
(a) Bone tumor in the proximal femur 
(b) Hip dislocation and tumor curettage  
(c) Rotation of the bony lesion connecting with the limb, which is then frozen in liquid nitrogen 
(d) Reconstruction using a hemiarthroplasty with bone cement 
 
Figure 3: X-ray images, bone-scintigram and intraoperative photograph 
(a) Preoperative radiography showing osteosarcoma of the distal femur 
(b) Preoperative bone scintigram showing multiple bone metastases in pelvis, lumber, humerus and 
so on.  
(c) Photograph of the cryotreatment method. The specimen was frozen in liquid nitrogen and 
reconstruction frozen autograft and total knee arthroplasty composite.   
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(d) Postoperative radiography showing composite reconstruction 
 
Figure 4: Pelvic computed tomography (CT) images pre- and post- DC immunotherapy after 
cryptreatment 
(a) Pelvis CT before DC immunotherapy, showing multiple bone metastases 
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Table 1. Immunological reaction of patients in reconstructions of malignant bone tumors using frozen autografts treated with liquid nitrogen 
Case Sex/age Site Diagnosis Follow‐up
IFN‐gamma EIA  IL‐12  Outcome
pre‐op. post‐op. 1M concentrations 1M post‐op. 3M concentrations 3M pre‐op. post‐op. 1M concentrations 1M post‐op. 3M concentrations 3M
(years)  (month) (IU/ml) (IU/ml) (%) (IU/ml) (%) (pg/ml) (pg/ml) (%) (pg/ml) (%)
1 M/65 radius metastasis of renal cell carcinoma 14  34.6 28.1 81.2  14.5 41.9  55.8 38.8 69.5  31.1 55.7  CDF
2 F/48 tibia osteosarcoma 21  54.7 36.8 67.3  21.7 39.7  7.8 7.8 100.0  7.8 100.0  CDF
3 F/17 femer osteosarcoma 18  8.3 6.3 75.9  8.7 104.8  7.8 7.8 100.0  7.8 100.0  CDF
4 F/71 femer metastasis of ureter carcinoma 15  32.9 45.1 137.1  45.7 138.9  33.8 11.4 33.7  57.1 168.9  AWD
5 M/20 tibia osteosarcoma 16  37.4 35.5 94.9  26.5 70.9  36.3 12.5 34.4  10.6 29.2  CDF
6 M/27 tibia osteosarcoma 16  65.3 11.7 17.9  57 87.3  165 7.8 4.7  7.8 4.7  CDF
7 M/51 femer osteosarcoma 16  123 163 132.5  58.1 47.2  34.1 296 868.0  7.8 22.9  CDF
8 M/14 tibia osteosarcoma 27  2.8 8.7 310.7  7.3 260.7  7.8 7.8 100.0  7.8 100.0  CDF
9 M/20 tibia osteosarcoma 14  10.7 5.1 47.7  28.5 266.4  7.8 7.8 100.0  51.2 656.4  CDF
10 M/18 femur osteosarcoma 11  145 134 92.4  54.3 37.4  82.3 199 241.8  103 125.2  CDF
11 M/15 femur osteosarcoma 8  2.5 21.2 848.0  67.9 2716.0  7.8 15.2 194.9  143 1833.3  CDF
12 F/49 femer metastasis of brest cancer 33  15.9 23.7 149.1  14.7  92.5  30.5 7.8 25.6  7.8 25.6  NED
13 F/18 femer metastasis of osteosarcoma 14  24.4 34.9 143.0  58.2  238.5  7.8 66 846.2  321 4115.4  DOD
14 F/12 humerous osteosarcoma 6  6.7 3.7 55.2  7.8 7.8 100.0  DOD
15 F/22 femur osteosarcoma 18  53.9 109 202.2  47.6  88.3  7.8 7.8 100.0  7.8 100.0  DOD
16 M/42 pelvis osteosarcoma 14  127 139 109.4  47.2  37.2  35.8 19.5 54.5  13 36.3  DOD
17 M/34 femur chondrosarcoma 29  14.4 42.9 297.9  47.6  330.6  9.9 15.1 152.5  8.7 87.9  CDF
18 M/62 femur periosteal osteosarcoma  25  45.6 31.6 69.3  54.3  119.1  7.8 7.8 100.0  15.4 197.4  NED
19 F/76 humerous metastasis of colon cancer  17  76.2 90 118.1  7.9 36.5 462.0  DOD
20 M/41 pelvis chondrosarcoma 25  88.8 130 146.4  55.4 54.1 97.7  CDF
21 M/52 pelvis metastasis of renal cancer 31  154 71.6 46.5  102 8.2 8.0  21.1 20.7  AWD
22 F/18 tibia osteosarcoma 25  78 5 6.4  86.8  111.3  47.5 7.8 16.4  AWD
23 M/73 femer metastasis of liver cell carcinoma 25  60 116 193.3  7.8 7.8 100.0  AWD
24 F/54 femer metastasis of renal cell carcinoma 24  12 33.7 280.8  12 79.7 664.2  NED
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